Company Overview - CMB.TECH is a diversified maritime group that owns and operates over 150 seagoing vessels, including crude oil tankers, dry bulk vessels, container ships, chemical tankers, offshore wind vessels, and workboats [3] - The company also provides hydrogen and ammonia fuel to customers, sourced from its own production or third-party producers [3] - CMB.TECH is headquartered in Antwerp, Belgium, with offices across Europe, Asia, the United States, and Africa [3] Financial Reporting - CMB.TECH published its annual report for the year ended December 31, 2024, in accordance with Belgian law, available on its website [1] - The annual report on Form 20-F was submitted to the U.S. Securities and Exchange Commission on April 9, 2025, and can be downloaded from the company's website [2] Stock Information - CMB.TECH is listed on Euronext Brussels and the NYSE under the ticker symbol CMBT [4]

Core Insights - Bio-Techne Corporation has expanded its partnership with Leica Biosystems to enhance spatial biology research through automation of the RNAscope™ Multiomic LS Assay and protease-free workflows [1][3] Company Overview - Bio-Techne is a global life sciences company that generated approximately $1.2 billion in net sales in fiscal 2024 and employs around 3,100 people worldwide [5] - Leica Biosystems is a leader in cancer diagnostics and workflow solutions, operating in over 100 countries and dedicated to advancing cancer diagnostics [6] Product Innovations - The RNAscope™ Multiomic LS Assay allows for the simultaneous fluorescent detection of up to six RNA and/or protein biomarkers on a single slide, preserving sample integrity [2] - ACD has introduced a protease-free workflow for RNAscope™ 2.5 single-plex assays on the Leica BOND RX staining instrument, enhancing multiomic visualization capabilities [2] Strategic Importance - The automation of RNAscope™ assays on the Leica BOND RX platform is seen as a significant milestone in spatial multiomics research, providing a fully automated solution that preserves sample integrity [3] - The partnership has been in place since 2015 and aims to streamline in-situ hybridization workflows, contributing to over 12,000 peer-reviewed publications [3]

Company Developments - Bio-Techne Corporation has opened a new Customer Experience Centre in Düsseldorf, Germany, aimed at enhancing customer service across the EMEA region and supporting long-term growth [1] - The new centre is set to open in the first half of 2026 and will complement the existing Demonstration Laboratory in the UK, chosen for its strategic location in a thriving life sciences sector [2] - The facility will feature a state-of-the-art Demonstration Laboratory showcasing Bio-Techne's full instrument portfolio, including the recently launched Leo System and the COMET spatial biology platform [3] Industry Prospects - The life science market is projected to grow at a compound annual growth rate (CAGR) of 10.28% from 2024 to 2033, driven by technological advancements, demand for personalized medicine, and increased R&D investments [4] Other Developments - Bio-Techne's brand Asuragen has partnered with Oxford Nanopore Technologies to launch the AmplideX Nanopore Carrier Plus Kit, a new genetic panel for carrier screening research [5] - The company has expanded its RNAscope in situ hybridization probes portfolio to over 70,000 unique probes across more than 450 species, enhancing spatial biology research [6] Competitive Landscape - Competitor QIAGEN N.V. has enhanced its QIAcuity dPCR system, doubling the number of targets analyzed from a single sample, and partnered with Genomics England for the 100,000 Genomes Project [8] - Thermo Fisher Scientific's Olink Explore Platform has been selected for the UK Biobank Pharma Proteomics Project, aiming to analyze over 5,400 proteins from 600,000 samples [9] - Bio-Rad has made advancements in its ddPCR platform and invested in Geneoscopy for a non-invasive colorectal cancer screening test [11]

Core Insights - Bio-Techne Corporation is opening a new Customer Experience Centre in Düsseldorf, Germany, aimed at enhancing customer engagement across the EMEA region and supporting long-term growth strategies [1][2] - The new facility will feature a state-of-the-art Demonstration Laboratory showcasing Bio-Techne's full instrument portfolio, allowing customers to gain hands-on experience [1] - Düsseldorf was selected for its strong life sciences sector and strategic location, facilitating access to multiple European markets [2] Company Overview - Bio-Techne Corporation is a global life sciences company that provides innovative tools and bioactive reagents for research and clinical diagnostics, generating approximately $1.2 billion in net sales in fiscal 2024 [3] - The company employs around 3,100 people worldwide and offers a wide range of products that assist in scientific investigations and drug discovery [3] - Recent product innovations include the Leo™ System, which automates western blot assays, and the COMET™ platform, known for its high-throughput tissue profiling capabilities [4]

Core Insights - Bio-Techne Corporation is advancing its strategy to enhance patient care through RNAscope technology, focusing on biomarker detection and pathology laboratory workflows [1][2] - The company will showcase these advancements at the USCAP Annual Meeting, highlighting the potential of RNAscope technology in clinical and translational research [1][2] Company Overview - Bio-Techne Corporation is a global life sciences company that provides innovative tools and bioactive reagents for research and clinical diagnostics, generating approximately $1.2 billion in net sales in fiscal 2024 [3] - The company employs around 3,100 individuals worldwide and offers a vast portfolio of products to assist in scientific investigations and drug discovery [3] Technology and Applications - RNAscope technology is being utilized by leading pathologists to detect clinically relevant biomarkers, which may improve performance and reduce time to results compared to existing methods [2][4] - Specific applications of RNAscope technology include the detection of TRIM63 mRNA in renal cell carcinoma, albumin mRNA in liver tumors, and point mutations in gynecologic tumors [4]

Core Insights - Bio-Techne Corporation has launched the Leo System, which utilizes Simple Western Technology to enhance bioanalytical workflows, allowing for faster market introduction of next-generation therapies [1][2]. Company Overview - Bio-Techne has a market capitalization of $9.24 billion, with a Zacks Consensus Estimate indicating a 5.1% year-over-year increase in fiscal 2025 earnings and a 5.5% revenue improvement [3]. Product Details - The Leo System can process up to 100 samples in a single 3-hour run, providing the necessary precision and reproducibility for regulatory submissions [4]. - Leo improves upon existing Simple Western platforms by enhancing sample throughput and protein quantitation reproducibility, and it includes advanced software for compliance with regulatory standards [5]. Customer Reception - Early adopters and beta testers have reported positive feedback on Leo's performance, data quality, and its applicability in various research areas, including clinical biomarker studies and gene therapy assays [6]. Industry Prospects - The global western blotting market is valued at $1.97 billion in 2024, with a projected compound annual growth rate (CAGR) of 6.01% from 2025 to 2030, driven by increasing research initiatives in biotech and pharma sectors [7]. Recent Developments - Bio-Techne's Asuragen brand has partnered with Oxford Nanopore Technologies to launch a new genetic panel for carrier screening research [10]. - The company has also expanded its RNAscope in situ hybridization probes, now covering over 70,000 unique probes across more than 450 species to support spatial biology research [11].

MINNEAPOLIS, March 10, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it has begun shipping the Leo™ System, powered by Simple Western™ Technology. Leo expands upon existing Simple Western platforms that offer automated protein size resolution and antibody-based protein detection by dramatically improving sample throughput and enhancing the reproducibility of protein quantitation. Leo offers the throughput and precision of standard ELISAs in a fully automated western blot as ...

Core Viewpoint - CMB.TECH NV has announced the acquisition of approximately 40.4% of Golden Ocean Group Limited's issued share capital through its subsidiary, marking a significant step in its diversification strategy [1][2][3] Group 1: Acquisition Details - CMB.TECH is acquiring 81,363,730 shares of Golden Ocean at a price of 14.49 USD per share, totaling approximately 1.18 billion USD [1] - The shares represent about 40.4% of Golden Ocean's issued share capital and approximately 40.8% of its outstanding shares with voting rights [1] - The transaction is expected to complete on 12 March 2025 and is not subject to any conditions [4] Group 2: Strategic Intent - The acquisition aligns with CMB.TECH's strategic objective of diversification, aiming to become a long-term shareholder in Golden Ocean and invest in a modern dry bulk fleet [2] - CEO Alexander Saverys emphasized the importance of this acquisition as a milestone in the company's diversification strategy and expressed intentions to engage with Golden Ocean's management to drive long-term growth and innovation [3] Group 3: Financial Considerations - CMB.TECH has identified a bank syndicate to refinance all or parts of Golden Ocean's current outstanding debt, indicating proactive financial management in light of the acquisition [4]

Core Viewpoint - Bio-Techne Corporation's partnership with Oxford Nanopore Technologies to launch the AmplideX Nanopore Carrier Plus Kit is expected to enhance its Diagnostics and Spatial Biology segment, despite a recent dip in stock price [1][2][3]. Company Developments - The AmplideX Nanopore Carrier Plus Kit is a new genetic panel designed for carrier screening research, providing a streamlined method for comprehensive sequencing data [1][6]. - Asuragen, a Bio-Techne brand, is recognized for high-quality molecular diagnostic products, and the partnership is anticipated to improve market sentiment towards Bio-Techne's stock [3]. - Bio-Techne has a market capitalization of $9.76 billion, with a Zacks Consensus Estimate indicating a 6.8% year-over-year increase in fiscal 2025 earnings and a 5.5% revenue improvement [4]. Product Significance - The AmplideX Nanopore Carrier Plus Kit addresses the updated ACMG recommendations for carrier screening, allowing for the analysis of genes not detectable by standard short-read sequencing [5]. - The kit includes a panel of 11 genes, such as CFTR and CYP21A2, which are prevalent but challenging to detect with traditional methods [6][7]. Industry Prospects - The global Nanopore Sequencing market is projected to grow from $330.59 million in 2023 to a compound annual growth rate (CAGR) of 18.07% through 2029, driven by increasing demand for DNA sequencing and technological advancements [8].

Core Insights - Cyber Enviro-Tech Inc. (CETI) has established a Turkish subsidiary, Cyber International Ltd (C-INT), to enhance its sludge pond and soil remediation capabilities in Turkey [1] - C-INT has formed a strategic alliance with Delta World Environmental Solutions (DELTA) to facilitate project management and execution in the region [2] - The partnership with DELTA is expected to leverage extensive relationships across Turkey, Africa, and the Middle East, positioning CETI for potential contracts with various overseas companies and government entities [2][3] Company Overview - CETI specializes in eco-conscious remediation of oil, sludge, water, and soil, utilizing bio-remedial materials and proprietary technologies [3] - The company focuses on cleaning contaminated sites, including oil/sludge ponds, storage tanks, and industrial wastewater [3] - CETI employs advanced technologies from the 4th Industrial Revolution, such as machine learning and artificial intelligence, in its remediation processes [3]